Therapeutic Response Statement (Sensitivity)
This therapeutic response statement supports the relationship that v::RET status confers therapeutic sensitivity to Vandetanib in patients with Medullary Thyroid Cancer.
The Republic of Ireland's Health Service Executive (HSE) has approved vandetanib for reimbursement as a monotherapy treatment option for the treatment of patients with unresectable, locally advanced, or metastatic medullary thyroid cancer (MTC) that is Rearranged during Transfection (RET) mutation positive.
This statement is based on a regulatory approval from the Health Service Executive:
Treatment of medullary thyroid cancer (MTC) in patients with Rearranged during Transfection (RET) mutation positive, unresectable locally advanced or metastatic disease.